Background: Hormone receptor signaling is critical in the progression of breast cancers, although the role of the androgen receptor (AR) remains unclear, particularly for estrogen receptor (ER)-negative tumors. This study assessed AR protein expression as a prognostic marker for breast cancer mortality. Methods: This study included 4147 pre- and postmenopausal women with invasive breast cancer from the Nurses' Health Study (diagnosed 1976-2008) and Nurses' Health Study II (1989-2008) cohorts. AR protein expression was evaluated by immunohistochemistry and scored through pathologist review and as a digitally quantified continuous measure. Hazard ratios (HR) and 95% confidence intervals (CI) of breast cancer mortality were estimated from Cox proportional hazards models, adjusting for patient, tumor, and treatment covariates. Results: Over a median 16.5 years of follow-up, there were 806 deaths due to breast cancer. In the 7 years following diagnosis, AR expression was associated with a 27% reduction in breast cancer mortality overall (multivariable HR = 0.73, 95% CI = 0.58 to 0.91) a 47% reduction for ER+ cancers (HR = 0.53, 95% CI = 0.41 to 0.69), and a 62% increase for ER- cancers (HR = 1.62, 95% CI = 1.18 to 2.22) (P heterogeneity < .001). A log-linear association was observed between AR expression and breast cancer mortality among ER- cancers (HR = 1.14, 95% CI = 1.02 to 1.26 per each 10% increase in AR), although no log-linear association was observed among ER+ cancers. Conclusions: AR expression was associated with improved prognosis in ER+ tumors and worse prognosis in ER- tumors in the first 5-10 years postdiagnosis. These findings support the continued evaluation of AR-targeted therapies for AR+/ER- breast cancers.
Dr Baker's abstract, "Effect of testosterone therapy on quantitative breast lobular atrophy in transmasculine individuals" has been accepted for a Poster presentation at theApplications of Medical AI Workshop at Medical Image Computing and Computer Assisted Intervention (MICCAI) Meeting, Singapore.
Congratulations to Dr Baker. Her abstract, "Comparing the Immunohistochemistry Scoring of Breast Tumor Tissue Microarrays Using Definiens, InForm, and QuPath" has been accepted for Poster presentation at the CAP annual meeting 2022.
Dr. Heng was one of the speakers at the BIDMC Precision RNA Medicine Core Detection Workshop, "Tools for the discovery and validation of clinically important microRNA biomarkers” on Friday, April 29th at 9:00 AM – 10:30 AM ET.
The title of her talk was, "“Plasma miRNAs associated with cisplatin sensitivity in breast cancer.”